Product Description
Mechanisms of Action: FXa Inhibitor,TFP Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Pneumonia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTFP561A2308 | P3 |
Completed |
Pneumonia |
2008-07-01 |
69% |
ACTRN12607000460404 | P3 |
Recruiting |
Pneumonia |
None |